Skip to main content

Advertisement

Articles

Page 1 of 39

  1. Content type: Review

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the p...

    Authors: Bridget P. Keenan, Lawrence Fong and Robin K. Kelley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:267

    Published on:

  2. Content type: Case report

    Nivolumab, a programmed death-1 (PD-1) inhibitor, is an immune checkpoint inhibitor particularly used in the treatment of malignant melanoma, non-small cell lung cancer and renal cell carcinoma. Immune-related...

    Authors: Saade Anastasia, Mansuet-Lupo Audrey, Arrondeau Jennifer, Thibault Constance, Mirabel Mariana, Goldwasser François, Oudard Stéphane and Weiss Laurence

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:266

    Published on:

  3. Content type: Short report

    The interplay between the immune system and tumor progression is well recognized. However, current human breast cancer immunophenotyping studies are mostly focused on primary tumors with metastatic breast canc...

    Authors: Li Zhu, Jessica L. Narloch, Sayali Onkar, Marion Joy, Gloria Broadwater, Catherine Luedke, Allison Hall, Rim Kim, Katherine Pogue-Geile, Sarah Sammons, Naema Nayyar, Ugonma Chukwueke, Priscilla K. Brastianos, Carey K. Anders, Adam C. Soloff, Dario A. A. Vignali…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:265

    Published on:

  4. Content type: Research article

    Immune checkpoint inhibitors (ICIs) have achieved impressive success in different cancer types, yet responses vary and predictive biomarkers are urgently needed. Growing evidence points to a link between DNA m...

    Authors: Hao-Xiang Wu, Yan-Xing Chen, Zi-Xian Wang, Qi Zhao, Ming-Ming He, Ying-Nan Wang, Feng Wang and Rui-Hua Xu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:264

    Published on:

  5. Content type: Review

    The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now ...

    Authors: Thorbald van Hall, Pascale André, Amir Horowitz, Dan Fu Ruan, Linda Borst, Robert Zerbib, Emilie Narni-Mancinelli, Sjoerd H. van der Burg and Eric Vivier

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:263

    Published on:

  6. Content type: Case report

    Immune checkpoint inhibitors have improved clinical outcomes including survival in several malignancies but have also been associated with a range of immune-related adverse events (irAEs). Neurological irAEs a...

    Authors: Catherine A. Gao, Urs M. Weber, Aldo J. Peixoto and Sarah A. Weiss

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:262

    Published on:

  7. Content type: Research article

    Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rate...

    Authors: Kamila Hladíková, Vladimír Koucký, Jan Bouček, Jan Laco, Marek Grega, Miroslav Hodek, Michal Zábrodský, Milan Vošmik, Kateřina Rozkošová, Hana Vošmiková, Petr Čelakovský, Viktor Chrobok, Aleš Ryška, Radek Špíšek and Anna Fialová

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:261

    Published on:

  8. Content type: Short report

    The tumor microenvironment exists in a state of dynamic equilibrium, in which a balance of agonist and antagonist signals govern the anti-tumor immune responses. Previous studies have shown that chemotherapy c...

    Authors: Tae Heung Kang, Chih-Ping Mao, Young Seob Kim, Tae Woo Kim, Andrew Yang, Brandon Lam, Ssu-Hsueh Tseng, Emily Farmer, Yeong-Min Park and Chien-Fu Hung

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:260

    Published on:

  9. Content type: Research article

    Natural killer (NK) cells are important anti-tumor cells of our innate immune system. Their anti-cancer activity is mediated through interaction of a wide array of activating and inhibitory receptors with thei...

    Authors: B. Martín-Antonio, G. Suñe, A. Najjar, L. Perez-Amill, A. Antoñana-Vildosola, M. Castella, S. León, M. Velasco-de Andrés, F. Lozano, E. Lozano, C. Bueno, J. M. Estanyol, C. Muñoz-Pinedo, S. N. Robinson and A. Urbano-Ispizua

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:259

    Published on:

  10. Content type: Review

    Prostate cancer (PCa) is one of the main causes of cancer-related death in men. In the present immunotherapy era, several immunotherapeutic agents have been evaluated in PCa with poor results, possibly due to its...

    Authors: Giuseppe Schepisi, Maria Concetta Cursano, Chiara Casadei, Cecilia Menna, Amelia Altavilla, Cristian Lolli, Claudio Cerchione, Giovanni Paganelli, Daniele Santini, Giuseppe Tonini, Giovanni Martinelli and Ugo De Giorgi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:258

    Published on:

  11. Content type: Research article

    Several mechanisms are present in the tumor microenvironment (TME) to impair cytotoxic T cell responses potentially able to control tumor growth. Among these, the accumulation of adenosine (Ado) contributes to...

    Authors: Beatris Mastelic-Gavillet, Blanca Navarro Rodrigo, Laure Décombaz, Haiping Wang, Giuseppe Ercolano, Rita Ahmed, Leyder Elena Lozano, Angela Ianaro, Laurent Derré, Massimo Valerio, Thomas Tawadros, Patrice Jichlinski, Tu Nguyen-Ngoc, Daniel E. Speiser, Grégory Verdeil, Nicolas Gestermann…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:257

    Published on:

  12. Content type: Short report

    Programmed cell death 1 inhibitors have revolutionized therapy for cancer by their outstanding effectiveness. However, they may cause adverse effects, among which inflammatory myopathy is one of the most disab...

    Authors: Shiro Matsubara, Morinobu Seki, Shigeaki Suzuki, Takashi Komori and Mikio Takamori

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:256

    Published on:

  13. Content type: Research article

    Pancreatic ductal adenocarcinoma (PDAC) is a highly devastating disease with an overall 5-year survival rate of less than 8%. New evidence indicates that PDAC cells release pro-inflammatory metabolites that in...

    Authors: Rosalinda Trovato, Alessandra Fiore, Sara Sartori, Stefania Canè, Rosalba Giugno, Luciano Cascione, Salvatore Paiella, Roberto Salvia, Francesco De Sanctis, Ornella Poffe, Cristina Anselmi, Francesca Hofer, Silvia Sartoris, Geny Piro, Carmine Carbone, Vincenzo Corbo…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:255

    Published on:

  14. Content type: Research article

    In melanoma, there is no companion diagnostic test to predict response to programmed cell death 1 (PD-1) axis immune checkpoint inhibitor (ICI) therapy. In the adjuvant setting, only one in five patients may b...

    Authors: Swati Gupta, Leena McCann, Yvonne G. Y. Chan, Edwin W. Lai, Wei Wei, Pok Fai Wong, James W. Smithy, Jodi Weidler, Brian Rhees, Michael Bates, Harriet M. Kluger and David L. Rimm

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:254

    Published on:

  15. Content type: Research article

    Adrenocortical carcinoma (ACC) is a rare malignancy without good treatment options. There are limited data about the use of immunotherapy in ACC. We investigated the efficacy and safety of pembrolizumab in pat...

    Authors: Mouhammed Amir Habra, Bettzy Stephen, Matthew Campbell, Kenneth Hess, Coya Tapia, Mingxuan Xu, Jordi Rodon Ahnert, Camilo Jimenez, Jeffrey E. Lee, Nancy D. Perrier, Russell R. Boraddus, Shubham Pant, Vivek Subbiah, David S. Hong, Abdulrazzak Zarifa, Siqing Fu…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:253

    Published on:

  16. Content type: Research article

    The US is experiencing an epidemic of HPV+ oropharyngeal cancers (OPC), the rates and burden of which now exceed that for cervical cancer. Immunotherapy targeting programmed death 1 (PD-1) on tumor-infiltrating l...

    Authors: Stephanie Dorta-Estremera, Venkatesh L. Hegde, Ravaen B. Slay, Rachel Sun, Ananta V. Yanamandra, Courtney Nicholas, Sita Nookala, Gloria Sierra, Michael A. Curran and K. Jagannadha Sastry

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:252

    Published on:

  17. Content type: Research article

    Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP f...

    Authors: Koji Haratani, Hidetoshi Hayashi, Takayuki Takahama, Yasushi Nakamura, Shuta Tomida, Takeshi Yoshida, Yasutaka Chiba, Takahiro Sawada, Kazuko Sakai, Yoshihiko Fujita, Yosuke Togashi, Junko Tanizaki, Hisato Kawakami, Akihiko Ito, Kazuto Nishio and Kazuhiko Nakagawa

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:251

    Published on:

  18. Content type: Research article

    Antibody-drug conjugates (ADCs) targeting the RON receptor, a tumorigenic factor contributing to cancer malignancy, has been considered as a novel strategy for cancer therapy. Here we describe a humanized anti...

    Authors: Xiang-Min Tong, Liang Feng, Sreedhar Reddy Suthe, Tian-Hao Weng, Chen-Yu Hu, Yi-Zhi Liu, Zhi-Gang Wu, Ming-Hai Wang and Hang-Ping Yao

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:250

    Published on:

  19. Content type: Research article

    There is strong evidence that immunotherapy-mediated tumor rejection can be driven by tumor-specific CD8+ T cells reinvigorated to recognize neoantigens derived from tumor somatic mutations. Thus, the frequenc...

    Authors: Michael Fehlings, Suchit Jhunjhunwala, Marcin Kowanetz, William E. O’Gorman, Priti S. Hegde, Hermi Sumatoh, Boon Heng Lee, Alessandra Nardin, Etienne Becht, Susan Flynn, Marcus Ballinger, Evan W. Newell and Mahesh Yadav

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:249

    Published on:

  20. Content type: Case report

    Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insuffi...

    Authors: Sahityasri Thapi, Amanda Leiter, Matthew Galsky and Emily J. Gallagher

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:248

    Published on:

  21. Content type: Research article

    Cancer immunotherapy has generated significant excitement, mainly as a result of the development of immune checkpoint inhibitors. The blockade of PD-1 or its ligand with antibodies has resulted in impressive c...

    Authors: Jing Shi, Chen Chen, Rui Ju, Qingzhu Wang, Juan Li, Lei Guo, Caiying Ye and Dechang Zhang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:246

    Published on:

  22. Content type: Research article

    PD-1/PD-L1 blockade has received approval for clinical application due to its encouraging benefit with improving prognosis in selected populations. Unfortunately, the response to immunotherapy for many patient...

    Authors: Fan Luo, Min Luo, Qi-Xiang Rong, Hong Zhang, Zhen Chen, Fang Wang, Hong-Yun Zhao and Li-Wu Fu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:245

    Published on:

  23. Content type: Research article

    Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation m...

    Authors: Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:244

    Published on:

  24. Content type: Research article

    Tumors can employ different mechanisms to evade immune surveillance and function. Overexpression of co-inhibitory ligands that bind to checkpoint molecules on the surface of T-cells can greatly impair the func...

    Authors: Shiran Hoogi, Vasyl Eisenberg, Shimrit Mayer, Astar Shamul, Tilda Barliya and Cyrille J. Cohen

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:243

    Published on:

  25. Content type: Research article

    The gut microbiome impacts the efficacy of immune checkpoint inhibitor (ICI) therapy and the development of ICI-mediated diarrhea and/or colitis (IMDC). Antibiotic therapy,especially that with anaerobic activity,...

    Authors: Hamzah Abu-Sbeih, Lauren Nicholas Herrera, Tenglong Tang, Mehmet Altan, Anne-Maria P. Chaftari, Pablo C. Okhuysen, Robert R. Jenq and Yinghong Wang

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:242

    Published on:

  26. Content type: Case report

    Autoimmune polyendocrine syndrome type II (APS-2) is a rare constellation of autoimmune hypoadrenalism, thyroid dysfunction and/or type 1 diabetes (T1DM), usually occurring in the 3rd or 4th decades and associ...

    Authors: Ashray Gunjur, Oliver Klein, Damien Kee and Jonathan Cebon

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:241

    Published on:

  27. Content type: Research article

    HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition...

    Authors: Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom and James L. Gulley

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:240

    Published on:

  28. Content type: Review

    Immune checkpoint inhibitors (ICBs) have revolutionized cancer treatment producing remarkable and durable responses for a range of malignancies. However, the additional modulation of immune response by ICBs ma...

    Authors: Amalia Anastasopoulou, Dimitrios C. Ziogas, Michael Samarkos, John M. Kirkwood and Helen Gogas

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:239

    Published on:

  29. Content type: Review

    Dendritic cells (DCs) are central players in the immune system, with an exquisite capacity to initiate and modulate immune responses. These functional characteristics have led to intense research on the develo...

    Authors: João Calmeiro, Mylène Carrascal, Célia Gomes, Amílcar Falcão, Maria Teresa Cruz and Bruno Miguel Neves

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:238

    Published on:

  30. Content type: Research article

    Preclinical evidence suggests that low-dose radiation may overcome the inhibitory effects of the tumor stroma and improve a tumor’s response to immunotherapy, when combined with high-dose radiation to another ...

    Authors: Hari Menon, Dawei Chen, Rishab Ramapriyan, Vivek Verma, Hampartsoum B. Barsoumian, Taylor R. Cushman, Ahmed I. Younes, Maria A. Cortez, Jeremy J. Erasmus, Patricia de Groot, Brett W. Carter, David S. Hong, Isabella C. Glitza, Renata Ferrarotto, Mehmet Altan, Adi Diab…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:237

    Published on:

  31. Content type: Research article

    Vulvar squamous cell carcinoma (VSCC) has been suggested to consist of three subtypes; HPV-positive, HPV-negative mutated TP53 or HPV-negative TP53 wildtype, with different clinical courses. To analyze the immune...

    Authors: Kim E. Kortekaas, Saskia J. Santegoets, Ziena Abdulrahman, Vanessa J. van Ham, Marij van der Tol, Ilina Ehsan, Helena C. van Doorn, Tjalling Bosse, Mariëtte I. E. van Poelgeest and Sjoerd H. van der Burg

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:236

    Published on:

  32. Content type: Commentary

    Advances in the immunotherapy of cancer have prolonged survival for cancer patients, but the clinical and financial impact of treatments must be considered in determining the overall clinical utility and econo...

    Authors: Peter Paul Yu, Omar Eton and Louis P. Garrison

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:235

    Published on:

  33. Content type: Correction

    Following publication of the original article [1], an error was noted in the GAPDH in the western blot depicted in Figure 4b.

    Authors: Kathleen E. Fenerty, Michelle Padget, Benjamin Wolfson, Sofia R. Gameiro, Zhen Su, John H. Lee, Shahrooz Rabizadeh, Patrick Soon-Shiong and James W. Hodge

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:234

    Published on:

    The original article was published in Journal for ImmunoTherapy of Cancer 2018 6:133

  34. Content type: Research article

    Programmed cell death protein 1 (PD-1) is a key immune checkpoint that regulates peripheral tolerance and protects against autoimmunity. Programmed death ligand-2 (PD-L2) is a less studied ligand to PD-1 and h...

    Authors: Yiyin Zhang, Jin Xu, Jie Hua, Jiang Liu, Chen Liang, Qingcai Meng, Miaoyan Wei, Bo Zhang, Xianjun Yu and Si Shi

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:233

    Published on:

  35. Content type: Research article

    T cell receptor-engineered T cells (TCR-Ts) therapy is a promising cancer treatment strategy. Nowadays, most studies focused on identification of high-avidity T cell receptors (TCRs) directed against neoantige...

    Authors: Qin Tan, Chaoting Zhang, Wenjun Yang, Ying Liu, Palashati Heyilimu, Dongdong Feng, Liying Xing, Yang Ke and Zheming Lu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:232

    Published on:

  36. Content type: Research article

    Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that play an important role in immune evasion, PD-1/PD-L1 inhibitor tolerance and tumour progression. Therefore, MDSCs are potential targets...

    Authors: Wanfeng Gao, Xiaoyun Zhang, Wendong Yang, Daolei Dou, Heng Zhang, Yuanhao Tang, Weilong Zhong, Jing Meng, Yun Bai, Yanrong Liu, Lan Yang, Shuang Chen, Huijuan Liu, Cheng Yang and Tao Sun

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:231

    Published on:

  37. Content type: Research article

    Myeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer r...

    Authors: Minjun C. Apodaca, Amy E. Wright, Angela M. Riggins, William P. Harris, Raymond S. Yeung, Lei Yu and Chihiro Morishima

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:230

    Published on:

  38. Content type: Short report

    T cell receptor (TCR) gene-engineered T cells have shown promise in the treatment of melanoma and synovial cell sarcoma, but their application to epithelial cancers has been limited. The identification of nove...

    Authors: Bridget Marcinkowski, Sanja Stevanović, Sarah R. Helman, Scott M. Norberg, Carylinda Serna, Benjamin Jin, Nikolaos Gkitsas, Tejas Kadakia, Andrew Warner, Jeremy L. Davis, Lisa Rooper and Christian S. Hinrichs

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:229

    Published on:

  39. Content type: Research article

    A sequential combination of radiochemotherapy/endocrinotherapy and cytokine-induced killer cell (CIK) infusion has been shown to be an effective therapy for post-mastectomy breast cancer based on statistical a...

    Authors: Zi-Qi Zhou, Jing-Jing Zhao, Qiu-Zhong Pan, Chang-Long Chen, Yuan Liu, Yan Tang, Qian Zhu, De-Sheng Weng and Jian-Chuan Xia

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:228

    Published on:

  40. Content type: Research article

    Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble...

    Authors: Jinyu Zhang, Pablo Saenz-lopez Larrocha, Bin Zhang, Derek Wainwright, Payal Dhar and Jennifer D. Wu

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:223

    Published on:

  41. Content type: Research article

    Samalizumab is a novel recombinant humanized monoclonal antibody that targets CD200, an immunoregulatory cell surface member of the immunoglobulin superfamily that dampens excessive immune responses and mainta...

    Authors: Daruka Mahadevan, Mark C. Lanasa, Charles Farber, Manjari Pandey, Maria Whelden, Susan J. Faas, Terrie Ulery, Anjli Kukreja, Lan Li, Camille L. Bedrosian, Xiaoping Zhang and Leonard T. Heffner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:227

    Published on:

  42. Content type: Short report

    Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune relat...

    Authors: Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong and Michael Dougan

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:226

    Published on:

  43. Content type: Research article

    The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies.

    Authors: Aung Naing, Jeffrey Infante, Sanjay Goel, Howard Burris, Chelsea Black, Shannon Marshall, Ikbel Achour, Susannah Barbee, Rena May, Chris Morehouse, Kristen Pollizzi, Xuyang Song, Keith Steele, Nairouz Elgeioushi, Farzana Walcott, Joyson Karakunnel…

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:225

    Published on:

  44. Content type: Review

    Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-...

    Authors: Arsen Osipov, May Tun Saung, Lei Zheng and Adrian G. Murphy

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:224

    Published on:

  45. Content type: Short report

    Despite major improvements in combatting metastatic melanoma since the advent of immunotherapy, the overall survival for patients with advanced disease remains low. Recently, there is a growing number of repor...

    Authors: Douglas Donnelly, Shirin Bajaj, Jaehong Yu, Miles Hsu, Arjun Balar, Anna Pavlick, Jeffrey Weber, Iman Osman and Judy Zhong

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:222

    Published on:

  46. Content type: Review

    As part of the 2018 Immunotherapy Bridge congress (November 28–29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy tod...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Sandra Demaria, Robert L. Ferris, Gordon J. Freeman, Roger S. Lo, Alberto Mantovani, Paul Nathan, Omid Hamid, Katerina Politi and Igor Puzanov

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:221

    Published on:

  47. Content type: Research article

    Efficient cancer therapy is sought not only for primary tumor treatment but also for the prevention of metastatic cancer growth. Immunotherapy has been shown to prevent cancer metastasis by inducing antigen-sp...

    Authors: Li Xu, Wei Zhang, Hae-Bin Park, Minseok Kwak, Junghwan Oh, Peter C. W. Lee and Jun-O Jin

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:220

    Published on:

  48. Content type: Research article

    Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosy...

    Authors: Kohei Shitara, Taroh Satoh, Satoru Iwasa, Kensei Yamaguchi, Kei Muro, Yoshito Komatsu, Tomohiro Nishina, Taito Esaki, Jun Hasegawa, Yasuyuki Kakurai, Emi Kamiyama, Tomoko Nakata, Kota Nakamura, Hayato Sakaki and Ichinosuke Hyodo

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:219

    Published on:

  49. Content type: Research article

    Prostate cancer is poorly responsive to immune checkpoint inhibition, yet a combination with radiotherapy may enhance the immune response. In this study, we combined radiotherapy with immune checkpoint inhibit...

    Authors: Stephanie O. Dudzinski, Brent D. Cameron, Jian Wang, Jeffrey C. Rathmell, Todd D. Giorgio and Austin N. Kirschner

    Citation: Journal for ImmunoTherapy of Cancer 2019 7:218

    Published on:

Annual Journal Metrics

Advertisement